27 April 2007
Landmark study highlights complex genetic risk factors behind type 2 diabetes
*** Embargoed until 19.00 British Summer Time (14.00 EST) Thursday 26 April 2007 ***
A UK collaboration of scientists - using patient data gathered in Tayside and Fife - has identified three new genes1 that predispose individuals to develop type 2 diabetes, bringing scientists a step closer towards understanding what causes this complex disease.
The study, jointly led by researchers at the University of Oxford and the Peninsula Medical School, Exeter, and forming part of the Wellcome Trust Case Control Consortium2 looked at over 2 billion pieces of genetic data and 6,000 people with type 2 diabetes and 8,000 controls to track down these three genes. In addition, they confirmed the link between the disease and a further two previously-identified genes.
The findings, published online today in the journal Science3, bring the total number of genes known to be involved in type 2 diabetes to nine, including the FTO gene reported by the same UK group two weeks ago. The FTO gene influences individual risk of type 2 diabetes through its effect on weight and obesity.
Type 2 diabetes occurs as a result of a failure of the body to produce enough insulin to maintain normal levels of glucose (sugar) in the blood. This failure is usually compounded by a reduction in the capacity of the insulin released to work properly in tissues such as muscle and fat (known as insulin resistance). It is a major cause of heart disease and stroke, as well as blindness and kidney failure.
There are currently around 200 million people who have type 2 diabetes worldwide, yet its underlying cause is poorly understood, limiting both treatment and prevention. Lifestyle factors, such as poor diet and lack of exercise have been known for some time to increase risk of developing the disease, but scientists are becoming increasingly aware of the role played by genetics.
For each of the three genes described in the paper, the researchers have found that there are two common “versions”, one of which is associated with an increased risk of developing type 2 diabetes, and the other with reduced risk. Each high-risk version increases the risk of type 2 diabetes by between 10 and 20 percent. All are common in the general population.
"This research helps us to understand that, for most people at least, an individual’s risk of developing diabetes as they get older is influenced by a number of genes, as well as by their environment," says Professor Mark McCarthy from the University of Oxford, one of the lead authors of the paper. "Clearly, the more 'high risk' alleles a person inherits, the higher the likelihood that they will go on to develop diabetes."
The exact role of the genes that have been implicated by these studies is still uncertain. However, two of them appear to be involved in the development, function and regeneration of insulin-producing beta cells, found within the pancreas. This finding is likely to help to answer a long-standing controversy in the diabetes field concerning the extent to which a reduced number of pancreatic beta-cells (as opposed to reduced function) contributes to the development of diabetes.
"We now have significantly more pieces to the jigsaw that will help us understand the mechanisms behind type 2 diabetes," says Professor Andrew Hattersley of the Peninsula Medical School, also a lead author on the paper. "Each piece of new knowledge takes us a step closer towards a future with improved prevention and treatment of this very significant condition."
The first important clues to the identities of these genes came from a genome-wide analysis conducted in 2,000 people with type 2 diabetes and 3,000 controls as part of the Wellcome Trust Case Control Consortium2. The Consortium is one of the biggest projects ever undertaken to identify the genetic variations that predispose people to or protect them from major diseases.
These initial findings were then confirmed by studying a further 9,000 samples from the UK, the majority of them from the Dundee area collected by researchers from University of Dundee Medical School.
"We are gathering more information all the time on what the genetic and environmental causes of diabetes areand this is a major step forward in that process," said Professor Andrew Morris, Chair of Diabetic Medicine at the University of Dundee and one of the authors of the Wellcome Trust report.
"The information we have gathered here in Dundee from the local population in Tayside and Fife - who have been truly magnificent in supporting our research - is among the most detailed held anywhere in the world and is playing a key role in developments like this."
"We are always extremely grateful that people agree to take part in research, and major findings like this are the reward. We are making real progress in fully understanding diabetes which will inevitably lead to better treatments for the disease, so there is clear benefit."
The research has been conducted in close collaboration with two other groups from the US and Scandinavia4,5 ,who were undertaking similar research studies in samples from Sweden and Finland. Their results, which have also identified the same three genes, are published today alongside the UK study. In a unique collaboration, these three international groups chose to combine forces rather than compete, resulting in the largest ever collaborative study of type 2 diabetes, involving over 32,000 subjects.
"The extraordinary achievements of this research project have only been made possible through the unique international collaboration," says Dr Mark Walport, Director the Wellcome Trust, which funded the UK study. "By sharing data and working together, the researchers have made significant progress in understanding the genetics underlying type 2 diabetes in a very short time."
Iain Frame, Research Manager at Diabetes UK, said: "Diabetes UK welcomes these exciting findings. It’s important to remember that Type 2 diabetes is a genetic condition and not just associated with lifestyle factors. This discovery will help us get closer to unravelling the genetics of the condition. If we can understand more about the genetics we can make real progress towards the prevention and treatment of Type 2 diabetes."
"Diabetes UK funded the original collection of samples at the beginning of this study. It is thanks to the collaborative efforts of Diabetes UK, a number of excellent researchers and the Wellcome Trust that this discovery has been possible."
Contact
Craig Brierley
Media Officer
The Wellcome Trust
T: 020 7611 7329
E: c.brierley@wellcome.ac.uk
Notes for editors
1. Genes identified by the UK study:
IGF2BP2 - This gene codes for a protein called insulin-like growth factor 2 binding protein 2. It is thought that this protein may be involved in the regulation of insulin secretion.
CDKAL1 - This gene codes for a protein called CDK5 regulatory subunit associated protein1-like1. The protein may affect the activity of the cyclin dependent kinase 5 (CDK5) protein, which also has a role in the regulation of insulin production and may influence other events within the insulin-producing (beta) cells of the pancreas.
CDKN2A and CDKN2B - The proteins produced by these two genes inhibit the activity of cyclin-dependent protein kinases, including one that has been shown to influence the growth of beta cells in mice. Interestingly, these genes have been heavily studied for their role in cancer, but their contribution to diabetes comes as a complete surprise. It is unclear which of the two genes, A or B, is most likely to be involved in type 2 diabetes.
2. The Wellcome Trust Case Control Consortium (WTCCC) is a collaboration of 24 leading human geneticists at a number of institutes throughout the UK, who are analysing over 19,000 DNA samples from patients suffering with different diseases to identify common genetic variations for each condition. It is searching for the genetic signposts for tuberculosis, coronary heart disease, type 1 diabetes, type 2 diabetes, rheumatoid arthritis, Crohn's disease, bipolar disorder and hypertension. As a second project the WTCCC is also analysing 15,000 polymorphic markers that alter protein sequence to look for genetic variations relating to another four diseases - breast cancer, autoimmune thyroid disease, multiple sclerosis and ankylosing spondylitis. http://www.wtccc.org.uk
3. "Replication of genome-wide association signals in UK reveals risk loci for type 2 diabetes" by Zeggini, E. et al; Science, published in advance online 26 April 2007.
4. The Diabetes Genetics Initiative is a collaboration of The Broad Institute, Cambridge, Mass.; Sweden’s Lund University and Novartis, Basel, Switzerland led by The Broad Institute’s David Altshuler, and Leif Groop (Malmo, Sweden)
5. The FUSION (Finland-United States Investigation Of NIDDM Genetics) study is a collaboration between researchers at the University of Michigan, Ann Arbor (Michael Boehnke); National Human Genome Research Institute (Francis Collins); University of North Carolina (Karen Mohlke), University of Southern California, Los Angeles (Richard Bergman) and the University of Helsinki (Jaakko Tuomilehto).
6. The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. http://www.wellcome.ac.uk
7. Oxford University's Medical Sciences Division is one of the largest biomedical research centres in Europe. It represents almost one-third of Oxford University's income and expenditure, and two-thirds of its external research income. Oxford's world-renowned global health programme is a leader in the fight against infectious diseases (such as malaria, HIV/AIDS, tuberculosis and avian flu) and other prevalent diseases (such as cancer, stroke, heart disease and diabetes). Key to its success is a long-standing network of dedicated Wellcome Trust-funded research units in Asia (Thailand, Laos and Vietnam) and Kenya, and work at the MRC Unit in The Gambia. Long-term studies of patients around the world are supported by basic science at Oxford and have led to many exciting developments, including potential vaccines for tuberculosis, malaria and HIV, which are in clinical trials. http://www.ox.ac.uk
8. The Peninsula Medical School is a partnership between the Universities of Exeter and Plymouth and the NHS within Devon and Cornwall. The school, established in 2000, is involved in research in many areas of medicine. However they have a particular interest in diabetes where there are many internationally recognised research groups. Professor Andrew Hattersley's team at the Diabetes Genetics Centre was awarded the Queen's Anniversary Prize in 2006 for their pioneering work in genetic diabetes in children and young adults. http://www.pms.ac.uk
9. Diabetes UK is the charity for people with diabetes, their family friends and carers. Our mission is to improve the lives of people with the condition and work towards a future without diabetes by funding research, campaigning and helping people live with the condition. Please visit www.diabetes.org.uk for more information, or call Sarah Milsom in the press office on 020 7424 1164. People can call the Diabetes UK Careline on 0845 120 2960 for further support and information about diabetes.
10. The University of Dundee is a major research centre into the causes of diabetes, cancer and cardiovascular disease. The University hosts the Dundee Diabetes Research Centre and is currently engaged in a major £3 million fundraising campaign for diabetes research.
The charity campaign aims to establish state-of-the-art outpatient clinical research facilities in Angus, Perth and Dundee, enabling scientists and doctors to work together to undertake research from "the cell to the community".
For media enquiries contact:
Roddy Isles
Head, Press Office
University of Dundee
Nethergate
Dundee, DD1 4HN
TEL: 01382 384910
E-MAIL: r.isles@dundee.ac.uk
|
|